Veterans, First Responders, and families supporting psychedelic medicine will be honored at the conference for their mental health challenges and the urgent need for better care and resources.
Itzel Barakat, Justin LaPree
Ketamine and other psychedelics show promise for psychiatric disorders, but their psychoactive effects complicate masking in trials. A triple-masked trial on 40 patients with depression found surprising results.
Boris D. Heifets
Aaron will discuss his work with autistic adults, emphasizing neurodiversity-affirming care and the potential of psychedelic approaches to improve mental health support for autistic individuals.
Aaron Paul Orsini, Angela Carter ND, Jeanna Eichenbaum
Ketamine, a WHO essential medicine, has long been used globally as an anesthetic. Its off-label use for depression is growing, sparking discussions on efficacy, safety, and regulation.
Raquel Bennet, Sunny Strasburg, Gita Vaid, Danielle M Herrera, Lauren Taus
Psychedelic-assisted therapies for adolescents are discussed, including the use of ketamine for treatment-resistant depression and the need for further studies and careful consideration of risks. Traditional use of plant medicines
Corine de Boer, Rebecca Kronman, Glauber Assis
Metastatic breast cancer-induced bone pain (CIBP) is a common, severe pain type affecting many patients, lacking effective treatment options. A proposed study explores LSD therapy's potential efficacy for CIBP treatment.
Stephen Ross
Psilocybin's therapeutic potential for various medical conditions is being explored, including pilot studies on Alzheimer's Disease and chronic Lyme Disease. Preliminary results and participant reports inform ongoing psilocybin-assisted treatments research.
Albert Garcia-Romeu
SmallPharma and Imperial collaborated on a recent DMT study in major depression, presenting findings from psychedelic trials in depression at PS2023.
David Erritzoe
Depression remains a major unmet medical need globally, with current medications often providing inadequate relief and leading to high costs. Psychedelic therapies, like psilocybin, show promise in revolutionizing mental health
Charles Raison
Dr. Sloshower presents results from a psilocybin-assisted therapy study for major depression, showing larger antidepressant effects than placebo, with lasting mood improvements. Dr. Kilpatrick discusses longitudinal case studies.
Jordan Sloshower, Stephanie Kilpatrick
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.